Less Ads, More Data, More Tools Register for FREE

Pin to quick picksNorman Broadb Regulatory News (NBB)

Share Price Information for Norman Broadb (NBB)

Share Price is delayed by 15 minutes
Get Live Data
194.00    0.00 (0.00%)
Bid:
0.00
Ask:
0.00
Spread: 8.00 (4.211%)
Market Cap: £3.60m
NBB Live PriceLast checked at - London Stock Exchange

Intraday Norman Broadb Share Chart

Trading Update

11 Jul 2022 07:00

RNS Number : 9178R
Norman Broadbent PLC
11 July 2022
 

Norman Broadbent plc

("Norman Broadbent", the "Company" or the "Group")

Trading Update

Norman Broadbent (AIM: NBB), a leading London quoted Executive Search and Interim Management firm offering a diversified portfolio of integrated Leadership Acquisition & Advisory Services, is pleased to provide the following trading update for the 6 months ended 30 June 2022 ("H1 2022").

Financial highlights

Net Fee Income

H1 2022

H1 2021

% Change

£'000

£'000

Executive Search

2,581

1,995

29%

Interim Management

715

752

-

---------

---------

Group Total

3,296

2,747

20%

 

· Following on from a strong Q4 2021, net fee income ("NFI") in H1 2022 increased by 20% to £3.3m (H1 2021: £2.7m) driven by growth in Executive Search NFI.

· Executive Search NFI grown by 29% to £2.6m (H1 2021: £2.0m) through culture change, increased focus on senior mandates and improved brand positioning across core sectors.

· Interim Management NFI slightly down year on year ("YOY") at £0.7m, however, an operational focus to grow the Company's book of long-term contractors versus purely fixed term contracts has seen a considerable increase in contractor numbers and recurring income from these long term contractors, providing additional H2 2022 NFI visibility of £0.2m.

· Average new search fee value increased by 30% YOY.

· Average NFI per fee earner up 40% YOY.

· 50% growth in number of fee earners since start of 2022.

· Days Sales Outstanding (DSO) reduced to 45 days as of 30 June 2022 (versus 66 days year-end 2021).

· New office openings scheduled in Scotland for H2 2022 to leverage industrial, financial services, retail / consumer, digital / technology and interim management practices across the UK. Experienced executive search leaders already recruited in Scotland to drive this market expansion.

· EBITDA for H1 2022 is expected to be in the range £40k to £60k, making progress to pre-covid earnings, but on a reshaped business built for growth. The Group will publish its unaudited interim results for the half year ended 30 June 2022 in mid-August 2022.

Kevin Davidson, Group CEO of Norman Broadbent plc, said:

 

"We are delighted with the progress the entire business has made and that this is quickly translating into improved financial performance whilst we continue to invest heavily in growth and business transformation. 

It is encouraging to see that our immediate focus on re-establishing Norman Broadbent's position at the forefront of executive and board search, along with rebuilding the interim runner book, are both bearing fruit. We have grown our team across multiple core sectors over the past 9 months, especially industrial, digital / technology and retail / consumer. Our Research and Insights team has also continued to expand, and all new appointments have established themselves quickly, adding to the evolving culture of the business and its future prospects.

With continued headcount growth, new office openings scheduled for H2 and a continued focus on higher value search and long-term recurring interim contractor income, I am confident in the trajectory the business is now on. There will clearly be some macro-economic headwinds in the coming months but with a relentless focus on quality, client satisfaction and culture we believe we can continue to build the business whilst generating sustainable profits in the years ahead."

 For further information, please contact:

Norman Broadbent plc

Kevin Davidson / Peter Searle / Steve Smith

 

020 7484 0000

WH Ireland LimitedJessica Cave / Darshan Patel

020 7220 1666

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTQVLFBLDLZBBX
Date   Source Headline
20th May 202610:40 amRNSResult of AGM
20th May 20267:00 amRNSAGM Statement
8th May 20267:00 amRNSDirectorate Change
28th Apr 20265:25 pmRNSCourt Approval of Capital Reduction
22nd Apr 20267:00 amRNSPosting of Annual Report & Notice of AGM
21st Apr 20267:00 amRNSQ1 2026 Trading Update
20th Apr 20267:00 amRNSDirectorate Change
31st Mar 20269:11 amRNSTotal Voting Rights
26th Mar 20262:00 pmRNSResult of General Meeting
25th Mar 20267:00 amRNSFinal Results
18th Mar 20268:00 amRNSHolding(s) in Company
10th Mar 20267:00 amRNSProposed Capital Reduction
9th Mar 20269:23 amRNSReplacement- Results Notice/Investor Presentation
9th Mar 20267:00 amRNSNotice of Interim Results & Investor Presentation
25th Feb 20267:00 amRNSAcquisition And Total Voting Rights
6th Feb 20267:03 amRNSDirectorate Change
21st Jan 20267:00 amRNSDirectorate Change
15th Jan 20267:00 amRNSQ4 and FY25 Trading Update
13th Oct 20257:00 amRNSQ3 2025 Trading Update
9th Sep 20257:00 amRNSChange of Auditor
8th Sep 20257:00 amRNSInterim Results
19th Aug 20257:00 amRNSNotice of Interim Results & Investor Presentation
11th Aug 20257:00 amRNSAppointment of Nominated Adviser and Sole Broker
10th Jul 20257:00 amRNSH1 2025 Trading Update
19th Jun 20252:49 pmRNSNotification of major holdings
19th Jun 20257:00 amRNSDirector/PDMR Shareholding
16th Jun 20257:00 amRNSDirector/PDMR Shareholding
22nd May 202512:58 pmRNSResult of AGM, Capital Reorganisation and TVR
22nd May 20257:00 amRNSAGM Statement
22nd Apr 20257:00 amRNSPosting of ARA & Notice of AGM
2nd Apr 20257:00 amRNSQ1 2025 Trading Update and Final Results
4th Mar 20257:00 amRNSNotice of Results & Investor Presentation
16th Jan 20257:00 amRNSTrading Update
16th Oct 20247:00 amRNSQ3 2024 Trading Update
11th Oct 20244:00 pmRNSDirector/PDMR shareholding
8th Oct 20247:00 amRNSDirector/PDMR Shareholding
3rd Oct 20247:00 amRNSChange of Registered Office
9th Sep 20247:00 amRNSInterim Results
19th Aug 20247:00 amRNSNotice of Interim Results & Investor Presentation
22nd Jul 20243:46 pmRNSNotification of major holdings
11th Jul 20247:00 amRNSH1 2024 Trading Update
23rd May 20245:29 pmRNSResult of Annual General Meeting
25th Apr 20247:00 amRNSQ1 2024 Trading Update
24th Apr 20247:00 amRNSSmall Cap Awards nomination
15th Apr 20243:18 pmRNSNotification of major holdings
8th Apr 202412:11 pmRNSIssue of Equity and Total Voting Rights
3rd Apr 20244:01 pmRNSNotification of major holdings
28th Mar 20247:00 amRNSPosting of ARA & Notice of AGM
27th Mar 20247:00 amRNSFinal Results
26th Mar 20244:07 pmRNSNotification of major holdings

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.